title: Position statement on efficiency of technologies for diabetes management.
abstract: Di@bet.es study results are impressive, showing that diabetes affects 13.8% of the Spanish population. Not only the statistical facts are alarming, but the increasing incidence of this disease is a major problem, as pandemic proportions of type 2 diabetes are expected. Thus, the study of diabetes represents a challenge not only for health services, but also for the Ministries of Health and Finance. Technology has become an essential tool in the quality are of patients with diabetes, as it helps in the healthcare processes to obtain an optimum metabolic balance and prevent possible complications. Insulin pumps, continuous glucose monitoring nd self-monitoring blood glucose have all proved their efficiency, and telemedicine it is making good progress. The indirect costs of diabetes in Spain are much higher than the directones, showing the importance of inverting the paradox. The optimization of resources depends not only on the ability of the physicians, but also the administration, to implant and sustain technological innovations in our system, and with that make it effective in terms of benefits. Cost-effectiveness and cost-utility analysis are needed to prioritize and allow health management services to make the correct choices for approaching this prevalent chronic disease.
authors.forename: Pilar
authors.initials: P
authors.lastname: Martín-Vaquero
authors.forename: María Asunción
authors.initials: MA
authors.lastname: Martínez-Brocca
authors.forename: José Manuel
authors.initials: JM
authors.lastname: García-López
mesh_terms: D015190:Blood Glucose Self-Monitoring / Q000191:economics / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003920:Diabetes Mellitus / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D019468:Disease Management; D014943:Global Health; D017048:Health Care Costs; D005102:Health Expenditures; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000191:economics / Q000706:statistics & numerical data; D062069:Inventions; D009313:National Health Programs / Q000191:economics; D013030:Spain / Q000453:epidemiology; D017216:Telemedicine / Q000191:economics; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin